| [1] |
SIEGEL RL, GIAQUINTO AN, JEMAL A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74( 1): 12- 49. DOI: 10.3322/caac.21820. |
| [2] |
CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66( 2): 115- 132. DOI: 10.3322/caac.21338. |
| [3] |
CUI JJ, FU QH, CHEN XB, et al. The real-world study of the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer in China[J]. J Pancreatol, 2023, 7: 1- 9. DOI: 10.1097/JP9.0000000000000155. |
| [4] |
CAO K, XIA YD, YAO JW, et al. Large-scale pancreatic cancer detection via non-contrast CT and deep learning[J]. Nat Med, 2023, 29: 3033- 3043. DOI: 10.1038/s41591-023-02640-w. |
| [5] |
Pancreatic Surgery Group, Surgery Branch of Chinese Medical Association; Professional Committee of Pancreatic Diseases, Chinese Research Hospital Association. The guideline for neoadjuvant therapy of pancreatic cancer in China(2020 edition)[J]. Med J Peking Union Med Coll Hosp, 2020, 11( 5): 547- 558. DOI: 10.3969/j.issn.1674-9081.2020.05.010. |
| [6] |
ZHANG TP, LIU YZ, REN B. Current status and challenges of total neoadjuvant therapy for pancreatic cancer[J]. Chin J Dig Surg, 2022, 21( 4): 461- 464. DOI: 10.3760/cma.j.cn115610-20220320-00141. |
| [7] |
WANG M, LI DW, CHEN RF, et al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: A multicentre, open-label, randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2021, 6( 6): 438- 447. DOI: 10.1016/S2468-1253(21)00054-6. |
| [8] |
WANG M, PENG B, LIU JH, et al. Practice patterns and perioperative outcomes of laparoscopic pancreaticoduodenectomy in China: A retrospective multicenter analysis of 1 029 patients[J]. Ann Surg, 2021, 273( 1): 145- 153. DOI: 10.1097/SLA.0000000000003190. |
| [9] |
SHI YS, WANG WS, QIU WH, et al. Learning curve from 450 cases of robot-assisted pancreaticoduocectomy in a high-volume pancreatic center: Optimization of operative procedure and a retrospective study[J]. Ann Surg, 2021, 274( 6): e1277- e1283. DOI: 10.1097/SLA.0000000000003664. |
| [10] |
WANG W, LOU W, XU Z, et al. Long-term outcomes of standard versus extended lymphadenectomy in pancreatoduodenectomy for pancreatic ductal adenocarcinoma: A Chinese multi-center prospective randomized controlled trial[J]. J Adv Res, 2023, 49: 151- 157. DOI: 10.1016/j.jare.2022.09.011. |
| [11] |
KHACHFE HH, NASSOUR I, HAMMAD AY, et al. Robotic pancreaticoduodenectomy: increased adoption and improved outcomes: is laparoscopy still justified?[J] Ann Surg, 2023, 278( 3): e563- e569. DOI: 10.1097/SLA.0000000000005687. |
| [12] |
ZWART MJW, van den BROEK B, DE GRAAF N, et al. The feasibility, proficiency, and mastery learning curves in 635 robotic pancreatoduodenectomies following a multicenter training program:“standing on the shoulders of giants”[J]. Ann Surg, 2023, 278( 6): e1232- e1241. DOI: 10.1097/sla.0000000000005928. |
| [13] |
WU WM, MIAO Y, YANG YM, et al. Real-world study of surgical treatment of pancreatic cancer in China: Annual report of China Pancreas Data Center(2016—2020)[J]. J Pancreatol, 2022, 5( 1): 1- 9. DOI: 10.1097/jp9.0000000000000086. |
| [14] |
WAINBERG ZA, MELISI D, MACARULLA T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma(NAPOLI 3): A randomised, open-label, phase 3 trial[J]. Lancet, 2023, 402( 10409): 1272- 1281. DOI: 10.1016/s0140-6736(23)01366-1. |
| [15] |
QIN S, LI J, BAI Y, et al. Nimotuzumab plus gemcitabine for K-ras wild-type locally advanced or metastatic pancreatic cancer[J]. J Clin Oncol, 2023, 41( 33): 5163- 5173. DOI: 10.1200/jco.22.02630. |
| [16] |
STRICKLER JH, SATAKE H, GEORGE TJ, et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer[J]. N Engl J Med, 2023, 388( 1): 33- 43. DOI: 10.1056/NEJMoa2208470. |
| [17] |
KEMP SB, CHENG N, MARKOSYAN N, et al. Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer[J]. Cancer Discov, 2023, 13( 2): 298- 311. DOI: 10.1158/2159-8290.CD-22-1066. |
| [18] |
QI C, LIU C, GONG J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results[J]. Nat Med, 2024, 30( 8): 2224- 2234. DOI: 10.1038/s41591-024-03037-z. |
| [19] |
PISHVAIAN MJ, BLAIS EM, BRODY JR, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: A retrospective analysis of the Know Your Tumor registry trial[J]. Lancet Oncol, 2020, 21( 4): 508- 518. DOI: 10.1016/S1470-2045(20)30074-7. |
| [20] |
AGUIRRE AJ, NOWAK JA, CAMARDA ND, et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine[J]. Cancer Discov, 2018, 8( 9): 1096- 1111. DOI: 10.1158/2159-8290.CD-18-0275. |
| [21] |
BAILEY P, CHANG DK, NONES K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer[J]. Nature, 2016, 531( 7592): 47- 52. DOI: 10.1038/nature16965. |
| [22] |
DREYER SB, UPSTILL-GODDARD R, LEGRINI A, et al. Genomic and molecular analyses identify molecular subtypes of pancreatic cancer recurrence[J]. Gastroenterology, 2022, 162( 1): 320- 324. e 4. DOI: 10.1053/j.gastro.2021.09.022. |
| [23] |
LOWERY MA, JORDAN EJ, BASTURK O, et al. Real-time genomic profiling of pancreatic ductal adenocarcinoma: Potential actionability and correlation with clinical phenotype[J]. Clin Cancer Res, 2017, 23( 20): 6094- 6100. DOI: 10.1158/1078-0432.CCR-17-0899. |
DownLoad: